This week
Suggest a nameObligation Marketing for AI Builders
The 7-Rung LadderThe 8-Type TaxonomyWrapper or WinnerThe Sample ColumnThe Signal
Updated through the day. Every headline links straight to the source. The two lines underneath are ours.
This is a useful reality check on agent capabilities in scientific domains. The takeaway is blunt: agents still struggle to reverse-engineer non-trivial research tools, even with training data and compute budgets. If you're building workflow automation for computational biology or chemistry, this tells you the ceiling on what agents can currently do unsupervised. PhD-level performance remains out of reach.
This is the supply-side move that unlocks biotech as a real AI frontier. Standardized, queryable datasets let models go beyond literature review into synthesis and prediction. For builders: biotech+AI is moving from toy problems to infrastructure. For investors: whoever owns this data layer owns the biotech AI stack.
The real signal here is that foundational science infrastructure is shifting from academic labs to AI companies. Google DeepMind's watermarking of biological systems and the emergence of an AI science economy mean that AI-driven research is moving upstream, into the design phase. If you're building tools for science, you need to understand this layer; if you're investing in science-adjacent AI, you should read the full piece to see which layer has margin.
This is the first clear signal that foundation models can conduct original research at scale, not just summarize existing work. For builders in biotech and drug discovery, this legitimizes Claude as a research instrument, not a documentation tool. For investors, it moves the needle on whether Claude's API pricing captures the actual value it generates.